1. Home
  2. MEG vs XERS Comparison

MEG vs XERS Comparison

Compare MEG & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Montrose Environmental Group Inc.

MEG

Montrose Environmental Group Inc.

HOLD

Current Price

$22.14

Market Cap

930.8M

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$6.16

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MEG
XERS
Founded
2012
2005
Country
United States
United States
Employees
3500
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
930.8M
1.0B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
MEG
XERS
Price
$22.14
$6.16
Analyst Decision
Buy
Buy
Analyst Count
4
6
Target Price
$35.25
$10.83
AVG Volume (30 Days)
238.0K
1.5M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
93.69
100.00
EPS
N/A
0.01
Revenue
$830,538,000.00
$49,590,000.00
Revenue This Year
$5.41
$34.37
Revenue Next Year
$7.19
$22.86
P/E Ratio
N/A
$642.00
Revenue Growth
19.26
142.67
52 Week Low
$19.00
$4.30
52 Week High
$32.00
$10.08

Technical Indicators

Market Signals
Indicator
MEG
XERS
Relative Strength Index (RSI) 52.09 50.24
Support Level $20.80 $5.79
Resistance Level $23.48 $6.41
Average True Range (ATR) 0.79 0.27
MACD 0.13 0.02
Stochastic Oscillator 88.92 28.07

Price Performance

Historical Comparison
MEG
XERS

About MEG Montrose Environmental Group Inc.

Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits and permits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, and soil remediation. The company derives maximum revenue from United States.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: